- Home
- EQC vs OBIO Comparison
EQC vs OBIO Comparison
Compare EQC & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQC
- OBIO
- Stock Information
- Founded
- EQC 1986
- OBIO 2017
- Country
- EQC United States
- OBIO United States
- Employees
- EQC N/A
- OBIO N/A
- Industry
- EQC Real Estate Investment Trusts
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- EQC Real Estate
- OBIO Health Care
- Exchange
- EQC Nasdaq
- OBIO Nasdaq
- Market Cap
- EQC 174.6M
- OBIO 151.3M
- IPO Year
- EQC 1986
- OBIO N/A
- Fundamental
- Price
- EQC $1.61
- OBIO $2.85
- Analyst Decision
- EQC
- OBIO Strong Buy
- Analyst Count
- EQC 0
- OBIO 5
- Target Price
- EQC N/A
- OBIO $15.00
- AVG Volume (30 Days)
- EQC 1.6M
- OBIO 69.1K
- Earning Date
- EQC 04-30-2025
- OBIO 05-12-2025
- Dividend Yield
- EQC N/A
- OBIO N/A
- EPS Growth
- EQC N/A
- OBIO N/A
- EPS
- EQC 0.26
- OBIO N/A
- Revenue
- EQC $57,570,000.00
- OBIO $2,638,000.00
- Revenue This Year
- EQC N/A
- OBIO $27.37
- Revenue Next Year
- EQC N/A
- OBIO $42.68
- P/E Ratio
- EQC $6.10
- OBIO N/A
- Revenue Growth
- EQC N/A
- OBIO N/A
- 52 Week Low
- EQC $1.40
- OBIO $2.49
- 52 Week High
- EQC $21.00
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- EQC 43.27
- OBIO 36.86
- Support Level
- EQC $1.58
- OBIO $2.75
- Resistance Level
- EQC $1.63
- OBIO $3.26
- Average True Range (ATR)
- EQC 0.02
- OBIO 0.48
- MACD
- EQC 0.01
- OBIO -0.01
- Stochastic Oscillator
- EQC 60.00
- OBIO 16.82
About EQC Equity Commonwealth of Beneficial Interest
Equity Commonwealth is a real estate investment trust engaged in the acquisition, ownership, and operation of office buildings located throughout the United States. The vast majority of the company's real estate portfolio comprises office assets. These properties are fairly evenly dispersed between many of America's urban markets, notably Washington, Austin and Denver. Equity Commonwealth derives the vast majority of its income in the form of rental revenue from tenants occupying its offices.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.